EMA’s Ben Venue Recommendations Confirm Interim Advice

The European Medicines Agency confirmed its initial advice and gave final recommendations for 12 out of 14 centrally authorized medicines manufactured at Ben Venue Laboratories’ Ohio site.

The medicines can continue to be prescribed as before, the EMA said today in an e-mailed statement. The drugs include Angiox, Busilvex, Vidaza, Vistide, Velcade, Ecalta diluent, Soliris, Cayston, Luminity, Mepact, Torisel and Vibativ, the EMA said.

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.